Results 101 to 110 of about 54,075 (219)

Hybrid modeling for optimizing cell cultivation in mAb production using a small‐scale automated experimental platform

AIChE Journal, Volume 72, Issue 5, May 2026.
Abstract This work presents the optimization of cell cultivation for monoclonal antibody (mAb) production. We developed a hybrid model describing the effects of multiple process variables on antibody productivity and impurity generation. An automated platform with 12 × 250 mL bioreactors was set up.
Kosuke Nemoto, Yuki Yoshiyama, Mizuki Morisasa, Junshin Iwabuchi, Yusuke Hayashi, Sara Badr, Hirokazu Sugiyama   +6 more
wiley   +1 more source

Immunoplasmonic Nanoprobes With Controlled Orientation Antibodies for Darkfield Microscopy Detection of Biomarker Proteins on Lung and Breast Cancer Cells

Analysis &Sensing, Volume 6, Issue 3, May 2026.
Protein AG enables controlled antibody orientation on gold nanoparticles. Using side‐illumination darkfield microscopy, these immunoplasmonic nanoprobes can be quantified on cancer cells to measure protein expression, with results consistent with immunofluorescence.
Scott G. Harroun, Isabelle Largillière, Sergiy Patskovsky, Dominique Trudel, Michel Meunier   +4 more
wiley   +1 more source

Immune‐Related Polyradiculoneuropathy Associated With Immune Checkpoint Inhibitors: A Comprehensive Case Series

Brain and Behavior, Volume 16, Issue 5, May 2026.
ABSTRACT Objective Immune‐related polyradiculoneuropathy (irPRN) is a rare but potentially severe neurological adverse event secondary to immune checkpoint inhibitors (ICIs), closely resembling Guillain–Barré syndrome. This study aims to characterize the clinical presentation, neurophysiological findings, therapeutic strategies, and clinical outcomes ...
A. Llauradó, E. Lainez, H. Ariño, M. Gratacòs‐Viñola, J. L. Seoane, M. Roca‐Herrera, J. L. Restrepo‐Vera, D. Sanchez‐Tejerina, N. Raguer, R. Juntas‐Morales   +9 more
wiley   +1 more source

Immunotherapy and Breast Reconstruction: Opportunities, Challenges, and Future Directions

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Immunotherapy is transforming breast cancer management, but it also presents new challenges for surgical and reconstructive practice. This review summarizes current evidence on immune checkpoint inhibitors, perioperative safety, and immune‐related adverse events, highlighting their impact on surgical timing, postoperative recovery, and ...
Shuang Li, Jianguo Wang, Yingjie Liu, Wenwu Cai, Weichang Zhang, Shengyun Li, Yunjian Zhang   +6 more
wiley   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Resistance to HER2-targeted therapy

Research in Molecular Medicine, 2013
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment.
Reza Valadan, Alireza Rafiei, Mohsen Tehrani, Forough Nejatollahi   +3 more
doaj  

Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide

Clinical &Translational Immunology, Volume 15, Issue 5, 2026.
Abstract Objectives The anti‐PD‐L1 antibody avelumab has demonstrated efficacy across multiple cancer types. Avelumab primarily blocks the PD‐1/L1 immune checkpoint, while inducing antibody‐dependent cellular cytotoxicity (ADCC) from CD16a+ NK cells.
Lachlan J Dobson, Barry D Hock, Ariana HT Drabble, Liping Goddard, Judith L McKenzie, Sean A MacPherson, Alexander D McLellan   +6 more
wiley   +1 more source

In Vivo Studies of [¹⁶¹Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2-Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression. [PDF]

J Nucl Med
Cold S, Sadasivam P, Wessel MM, Ischyropoulou M, Fonslet J, Engel TB, Nielsen CH, Kjaer A, Kristensen LK.   +8 more
europepmc   +1 more source

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Neoadjuvant disitamab vedotin combined with camrelizumab and S‐1 achieved high pathological response rates with manageable safety in resectable HER2‐overexpressing gastric and gastroesophageal junction cancer. Longitudinal circulating tumour DNA methylation profiling enabled dynamic monitoring of molecular response during treatment.
Longgang Wang, Bing Liu, Luguang Liu, Liqing Liu, Rong Li, Shumei Han, Xu Sun, Bo Bi, Yuanlin Sun, Dong Sun, Jie Chai   +10 more
wiley   +1 more source